Covid19
Pfizer, Moderna hit with new Alnylam patent lawsuits over COVID-19 vaccines | Reuters
/cloudfront-us-east-2.images.arcpublishing.com/reuters/ZVPMKK5DIZOJZFWCQ4HHFM6KYU.jpg)
Pfizer earned $37.8 billion from sales of its COVID-19 vaccine Comirnaty last year, while Moderna made $18.4 billion from its vaccine Spikevax.
Pfizer earned $37.8 billion from sales of its COVID-19 vaccine Comirnaty last year, while Moderna made $18.4 billion from its vaccine Spikevax.
